REGENXBIO Inc. operates as a biotechnology company. The Company focuses on the development, commercialization, and licensing of recombinant, and adeno-associated virus gene therapy. REGENXBIO serves customers worldwide.

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2025-11-06)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

REGENXBIO Inc (RGNX US)

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2025-11-06)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-08-18)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)